Introduction
============

Over the past decades, the treatments for lung cancer have progressed with the recognition of interindividual variation, leading to classification according to subtype and histology-based treatment strategies.[@b1-ott-7-1423]--[@b4-ott-7-1423] Lung adenocarcinoma is one of the histological subsets accounting for nearly 40% of all lung cancer cases. Its treatments have further advanced after the delineation of disease subgroups harboring specific mutant oncogenic kinases, such as epidermal growth factor receptor (EGFR), which respond to their corresponding tyrosine kinase inhibitors (TKIs).[@b5-ott-7-1423]--[@b7-ott-7-1423] With the increasing number of the so-called "driver" mutations identified in lung adenocarcinoma,[@b8-ott-7-1423] other prime examples, such as anaphylactic lymphoma kinase (ALK) and its inhibitor crizotinib, continue to emerge and provide patients with molecular-based treatments.[@b9-ott-7-1423]--[@b12-ott-7-1423] Therefore, lung adenocarcinomas could be classified in the genetic dimension by using mutant genes corresponding to the potential targeted molecular therapies.[@b13-ott-7-1423]

Recently, a new classification system was proposed by the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) to characterize further lung adenocarcinoma in the morphological dimension.[@b14-ott-7-1423] This approach segregates primary lesions considering their invasiveness and predominant histological pattern. Previous studies showed the association of this novel classification system with tumor metabolism,[@b15-ott-7-1423],[@b16-ott-7-1423] response to radiation,[@b17-ott-7-1423] and prognosis prediction,[@b17-ott-7-1423]--[@b21-ott-7-1423] indicating its role as a supplement to stage-dependent clinical decision-making.

To better characterize patients for clinical evaluation and treatment, we sought to evaluate whether these two classification systems correlate with each other and whether the combination of these two dimensions might produce subgroups that are more homogeneous. Several previous studies, all with relatively small sample sizes, reported a possible relationship between the IASLC/ATS/ERS classification and the *EGFR* and/or the *KRAS* mutation status.[@b21-ott-7-1423]--[@b25-ott-7-1423] In this study, we comprehensively analyzed 1,015 lung adenocarcinomas for driver mutations by using the IASLC/ATS/ERS classification and incorporated these data with the clinicopathological characteristics to evaluate their mutual correlation and potential role in prognostic prediction.

Materials and methods
=====================

Patients and tissues
--------------------

From February 2007--July 2012, surgically resected tumor samples from 1,015 patients with newly diagnosed, pathologically confirmed lung adenocarcinomas were consecutively collected by the Department of Thoracic Surgery at the Fudan University Shanghai Cancer Center. These tumor samples were taken at the time of surgical resection, and the tumor content was at least 20% evaluated by the pathologist. Among them, 24 patients received neoadjuvant chemotherapy, and ten cases that could not be pathologically/genetically classified were excluded; therefore, 981 completely resected lung adenocarcinomas were assessed for their genetic and morphological classification ([Figure S1](#SD1-ott-7-1423){ref-type="supplementary-material"}).

Genomic deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) was extracted from frozen tissues as per standard protocols (RNeasy Mini Kit and QiAamp DNA Mini Kit; Qiagen NV, Venlo, the Netherlands). The total RNA samples were then reverse-transcribed into single-stranded cDNA by using a RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Clinical and pathological data, including the age at diagnosis, sex, smoking history, and the pathological tumor, node, metastasis stage, were prospectively collected for analyses. Patients were followed-up in the clinic and/or by telephone for disease recurrence and survival from the date of diagnosis. This research was approved by the institutional review board of the Fudan University Cancer Center, Shanghai, People's Republic of China. All participants provided written informed consent.

Morphological and genetic classification evaluation
---------------------------------------------------

The novel classification of adenocarcinoma was reviewed by two pathologists (Yuan Li and Lei Shen), according to the criteria of the IASLC/ATS/ERS classification as previously described.[@b24-ott-7-1423],[@b25-ott-7-1423] For invasive adenocarcinoma, the predominant pattern was recorded and designated into three pattern groups for survival analysis, as suggested by previous studies:[@b15-ott-7-1423],[@b17-ott-7-1423],[@b19-ott-7-1423],[@b26-ott-7-1423] group 1 refers to lepidic predominant (LEP); group 2 refers to acinar predominant (ACN) or papillary predominant (PAP); and group 3 refers to micropapillary predominant (MP) or solid predominant (SLD) adenocarcinomas. Invasive mucinous adenocarcinoma (IMA) and other variants of invasive adenocarcinoma were analyzed separately, by using the IASLC/ATS/ERS guidelines.

A comprehensive analysis for driver mutations, including the *EGFR*, *KRAS*, *HER2*, *BRAF*, *ALK*, *RET*, and *PIK3CA,* was carried out as previously described.[@b13-ott-7-1423],[@b24-ott-7-1423],[@b27-ott-7-1423],[@b28-ott-7-1423] Briefly, *EGFR* (exons 18--22), *HER2* (exons 18--21), *KRAS* (exons 2--3), *BRAF* (exons 11--15), and *PIK3CA* (exons 9--20) were amplified by using the polymerase chain reaction (PCR) with cDNA used for Sanger sequencing. The *ALK* and *RET* rearrangements were screened by using PCR and quantitative real-time PCR with cDNA[@b27-ott-7-1423],[@b28-ott-7-1423] and confirmed with fluorescence in situ hybridization in formalin-fixed paraffin-embedded specimens.[@b27-ott-7-1423],[@b28-ott-7-1423]

Statistical analyses
--------------------

Associations between genetic, morphological, and clinical characteristics were analyzed by using the χ^2^ test or the Fisher's exact test. Patients who were diagnosed with stage I--IIIA lung adenocarcinoma from October 2007--August 2011 were followed-up until June 2012 for relapse-free survival (RFS) and overall survival (OS) analyses ([Figure S1](#SD1-ott-7-1423){ref-type="supplementary-material"}). The survival curves were estimated by using the Kaplan--Meier method with differences in survival assessed using the log-rank test. The multivariate survival analysis was conducted using the Cox proportional hazards model. All data were analyzed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). The two-sided significance level was set at *P*\<0.05.

Results
=======

In total, completely resected tumors from 981 patients with lung adenocarcinoma were eligible for examination and analyses, including 13 preinvasive lesions, 20 minimally invasive adenocarcinomas (MIAs), 901 invasive adenocarcinomas, 44 IMAs, and three colloid/enteric adenocarcinomas. The 901 patients with invasive adenocarcinoma consisted of 71 LEP, 488 ACN, 155 PAP, 24 MP, and 163 SLD subtypes. The patients' characteristics, according to the criteria of the IASLC/ATS/ERS classification, are shown in [Table 1](#t1-ott-7-1423){ref-type="table"}, and the overall mutational spectrum is shown in [Figure S2](#SD2-ott-7-1423){ref-type="supplementary-material"}. (Characteristics of the three colloid/enteric adenocarcinomas are shown in [Table S3](#SD7-ott-7-1423){ref-type="supplementary-material"}.)

Driver mutations partially correlate with IASLC/ATS/ERS classification
----------------------------------------------------------------------

The spectrum of driver mutations across the IASLC/ATS/ERS classifications is illustrated in [Figure 1](#f1-ott-7-1423){ref-type="fig"}. All driver mutations were mutually exclusive except in 18 patients with coexisting *EGFR* and *PIK3CA* mutations, four with both the *KRAS* and *PIK3CA* mutations, and one with both the *RET* and *PIK3CA* mutations. The overall frequency of the *EGFR* mutation was 64.7%, much higher than that reported in the Caucasian population, while the overall frequency of the *KRAS* mutation was 7.1%, much lower than that reported in Caucasian patients.[@b29-ott-7-1423]

MIA has a comparable mutation spectrum to invasive adenocarcinoma in terms of the frequency of the *EGFR* mutants (*P*=0.334) and pan-negative samples (*P*=1.000). Surprisingly, the samples from preinvasive lesions (atypical adenomatous hyperplasia \[AAH\]/adenocarcinoma in situ \[AIS\]) were found to have a significantly lower *EGFR* mutation frequency (*P*=0.013), but higher *HER2* and *BRAF* mutation frequencies than invasive adenocarcinoma (*P*=0.015 and *P*=0.003, respectively).

Interestingly, IMA was found to have a significantly lower prevalence of *EGFR* mutations but a higher prevalence of *KRAS*, *HER2,* and *ALK* mutations than invasive adenocarcinoma (*P*\<0.001, *P*\<0.001, *P*=0.003, and *P*=0.003, respectively). The difference was significant even when compared with MIA (*P*\<0.001, *P*=0.001, *P*=0.656, and *P*=0.049, respectively) or LEP invasive adenocarcinoma (*P*\<0.001, *P*\<0.001, *P*=0.030, and *P*=0.007, respectively).

For 901 invasive adenocarcinomas, the prevalence of *EGFR* mutants (*P*=0.404) and pan-negative samples (*P*=0.995) was relatively equal among the LEP, ACN, PAP, and MP patterns. However, SLD patterns had a significantly lower *EGFR* mutation frequency (*P*\<0.001) and a higher pan-negative frequency (*P*\<0.001) than non-SLD patterns. [Table S1](#SD5-ott-7-1423){ref-type="supplementary-material"} summarizes the correlation between driver mutations and clinical and pathological characteristics. Univariate analysis revealed a significant association of *KRAS* mutations with men (*P*\<0.001), smokers (*P*\<0.001), and SLD pattern adenocarcinomas (*P*\<0.001), and the tendency for the *ALK* fusions was significantly associated with invasive adenocarcinomas with a minor mucinous component (*P*\<0.001). Multivariate analysis ([Table S2](#SD6-ott-7-1423){ref-type="supplementary-material"}) confirmed smoking status and SLD pattern as independent factors predicting fewer *EGFR* mutants and more pan-negative tumors. The pan-negative tumors were also independently associated with older age (\>60 years), although it was not significant in the univariate analysis, while *EGFR* mutant tumors were also independently correlated with the absence of a mucinous component. Characteristics of one colloid, two enteric, and four stage III--IV adenocarcinomas with LEP pattern are listed in [Table S3](#SD7-ott-7-1423){ref-type="supplementary-material"}.

Mucinous component and smoking status indicate mutational test priority
-----------------------------------------------------------------------

Considering the predominant prevalence of *EGFR* mutations in this Chinese cohort, independent factors, including a minor mucinous component, smoking status, and SLD pattern were used to investigate a practical mutational test strategy in invasive adenocarcinomas. As demonstrated in [Figure 2](#f2-ott-7-1423){ref-type="fig"}, the frequency of *EGFR* mutations decreased and that of pan-negative tumors increased in smokers and in patients with SLD adenocarcinoma. The *KRAS* mutations were more common in smokers without a mucinous component, and the *ALK* mutations were more common in invasive adenocarcinomas with a minor mucinous component. *EGFR* remains the major genetic subtype in either subgroup.

Impact of genetic and morphological classifications on prognosis
----------------------------------------------------------------

The survival data of eight patients with preinvasive lesions or MIAs, 478 patients with stage I--IIIA invasive adenocarcinoma, and 17 patients with stage I--IIIA IMA were collected for RFS and OS analyses. Of these, 277 received adjuvant chemotherapy, with 266 (96.0%) treated with platinum-based doublets and eleven (4.0%) with a single regimen. No patient received TKIs as adjuvant chemotherapy. The median follow-up time was 19.0 months.

As listed in [Table S4](#SD8-ott-7-1423){ref-type="supplementary-material"}, the sex, smoking status, pathological stage, adjuvant chemotherapy, and histological pattern group were significantly associated with RFS, while the pathological stage, adjuvant chemotherapy, pattern group, and *EGFR* mutations were significantly associated with OS. As shown in [Table 2](#t2-ott-7-1423){ref-type="table"}, the pathological stage and histological pattern group remained the only independent predictors of RFS, and the pathologic stage was the only independent predictor of OS in the multivariate analysis.

None of the eight patients with preinvasive lesions or MIA had disease recurrence or death during follow-up. Predominant histological pattern and pattern group were significantly associated with RFS (*P*\<0.001 and *P*\<0.001, respectively) and OS (*P*=0.055 and *P*=0.018, respectively). Multivariate analysis confirmed the pattern group as an independent predictor for RFS (*P*=0.001) but not for OS (*P*=0.406). The group 1 (LEP) patients had the most favorable outcome, followed by group 2 (CAN and PAP), and by group 3 (SLD and MP) ([Figure S3](#SD3-ott-7-1423){ref-type="supplementary-material"}). Patients with IMA had a moderate-to-poor prognosis that could not be differentiated from group 2 or group 3 ([Figure S3](#SD3-ott-7-1423){ref-type="supplementary-material"}).

Generally, driver mutations had no impact on RFS (*P*=0.290) or OS (*P*=0.160) for invasive adenocarcinoma. However, there was a trend toward a poorer prognosis for patients harboring *HER2*, *BRAF,* or *ALK* mutations versus those with *EGFR* mutations, and the difference in OS between patients with *EGFR* and *HER2* or *KRAS* mutants was statistically significant ([Figure S4](#SD4-ott-7-1423){ref-type="supplementary-material"}).

We further investigated whether genetic classification had an impact on survival when it was combined with morphological classification. In the subgroup analysis for patients with stage IIIA tumors ([Figure 3](#f3-ott-7-1423){ref-type="fig"}), the pattern group 2 (ACN and PAP) tumors harboring *KRAS*/*HER2*/*BRAF* mutations conferred significantly poorer RFS than group 2 and even group 3 (SLD and MP) tumors that did not harbor any *KRAS*/*HER2*/*BRAF* mutations. However, there was no significant difference between *KRAS*/*HER2*/*BRAF* mutants and the wild-type tumors in group 3 patients. Although the comparison of the OS did not show any statistical significance, a similar trend suggested that the combination of genetic and morphological classification might define a distinct prognostic subgroup.

We also found that in the subcohort of patients harboring a wild-type *EGFR* gene, the histological pattern group was no longer an independent predictor of RFS, but the adjuvant chemotherapy was ([Table 2](#t2-ott-7-1423){ref-type="table"}), suggesting that genetic factors might modify the impact of morphological classification on prognosis.

Discussion
==========

The diverse responses and/or prognoses of patients reinforce that interindividual variation exists, and that specialized treatment is required. Recurrent kinase mutation analysis provides a genetic approach to scale these variations, according to the patients' potential responses to targeted therapy. The novel IASLC/ATS/ERS classification system provides a morphological predictor of prognosis, and possibly, of therapy response. Therefore, the integration of these two classifications might help to combine both kinds of information, potentially extending our understanding of lung adenocarcinoma. Although detected in several small set studies, the correlation between these two classification systems is still far from clear and their common impact on prognosis remains unknown. To the best of our knowledge, this is the largest scale study that used a comprehensive approach to investigate the correlation between the IASLC/ATS/ERS classification and the driver mutations and to evaluate their combined impact on prognosis.

The distribution of driver mutations partially correlated with the novel IASLC/ATS/ERS classification system. The MIA had a higher *EGFR* mutation frequency than invasive adenocarcinoma and IMA. For invasive adenocarcinoma, LEP had the largest *EGFR* mutation frequency followed by PAP, ACN, MP, and SLD. SLD was an independent predictor of *KRAS* and *RET* mutations, and the existence of a minor mucinous component was independently associated with a relatively high prevalence of *HER2* and *ALK* mutations. Either SLD or a mucinous component indicated a reduced chance of harboring a mutant *EGFR* gene. However, no morphological characteristics could identify a specific genetic subtype, suggesting that genetic heterogeneity remains a morphological scale.

One interesting finding in this study cohort was that preinvasive lesions (AAH/AIS) had a relatively lower *EGFR* mutation frequency but had a higher frequency of *HER2* and *BRAF* mutations. This finding greatly differs from the report by Yoshizawa et al, in which more than 80% of AIS patients harbored an *EGFR* mutation.[@b21-ott-7-1423] In addition, Sakamoto et al reported that AAH had a higher frequency of *KRAS* mutation (33%), which was low in AIS (12%) and MIA (8%).[@b30-ott-7-1423] Therefore, the mechanism behind the carcinogenesis driven by the mutant kinases and the pathological pathway underlying this process still warrant further investigation.

One of the great developments of the novel IASLC/ATS/ERS classification system is the replacement of previous bronchioloalveolar carcinoma with MIA, LEP, and IMA.[@b14-ott-7-1423] Earlier studies showed the association of the bronchioloalveolar carcinoma subtype with *EGFR* mutations.[@b31-ott-7-1423] Given this novel morphological insight, we found that IMA was associated with fewer *EGFR* mutations and more *KRAS*, *HER2*, and *ALK* mutations, indicating a different genetic background in this group of tumors. Survival analysis also revealed a poorer RFS and OS for patients with IMA than for patients with MIA or LEP. These data support the separation of IMA from the old bronchioloalveolar carcinoma classification.

The National Comprehensive Cancer Network guidelines recommend that biomarkers including *EGFR* and *ALK* should be initially tested for advanced nonsquamous non-small-cell lung cancer.[@b32-ott-7-1423] While the molecular testing guidelines by the College of American Pathologists, the IASLC, and the Association for Molecular Pathology[@b33-ott-7-1423] suggest that the laboratories may implement testing algorithms to enhance the efficiency of molecular testing of lung adenocarcinomas. When incorporated with the novel IASLC/ATS/ERS classification, we may propose an efficient mutation test algorithm for Chinese or East Asian patients ([Figure 4](#f4-ott-7-1423){ref-type="fig"}). Patients with AAH/AIS showing a favorable prognosis might not need a mutational test, and patients with MIA should undergo *EGFR* testing first, owing to its predominant prevalence. As a mucinous component and smoking were found to harbor diverse mutation spectrums in invasive adenocarcinoma, tumors with a mucinous component are recommended to receive *ALK* testing with or after testing for *EGFR* mutations, and patients who are smokers are recommended to be screened for the *KRAS* mutations with or after screening for *EGFR* mutations. IMA had a unique mutation distribution; therefore, this group of patients is recommended to undergo *KRAS* testing first, followed by *ALK* and *EGFR* mutation detection. Given that more and more oncogenes, including KRAS[@b34-ott-7-1423] and RET, are targetable (ie, cabozantinib),[@b35-ott-7-1423] this testing strategy might not only facilitate laboratory work flow but also the physicians' decision-making on target therapy.

The novel IASLC/ATS/ERS classification is excellent for outcome prediction; patients with preinvasive lesions and MIAs had no recurrence or death during follow-up. For invasive adenocarcinoma, a previous study showed that pattern group was an independent predictor for both disease-free survival and OS;[@b17-ott-7-1423] however, in this study cohort, we only validated the pattern group as an independent predictor of RFS, but not for OS. Potential reasons for this discrepancy might be the relatively short period of follow-up in our study, and that only patients with stage I--IIIA tumors were included in the survival analysis in our study to achieve more reproducible results in the surgical setting. Genetic classification according to driver mutations generally had no independent impact on the RFS or OS, although a trend toward improved outcomes for *EGFR* mutant tumors, similar to what was observed in previous studies of resected non-small-cell lung cancers,[@b36-ott-7-1423] was observed.

The addition of morphological classification by using the IASLC/ATS/ERS criteria increased the discriminative ability for predicting outcome; however, patients were still grouped in several specific patterns (eg, ACN and PAP). Therefore, the necessity to identify further patients with different outcomes is questioned. Kadota et al assessed the expression level of thyroid transcription factor-1 by using immunohistochemical staining to identify patients with early disease recurrence in stage I lung adenocarcinomas.[@b18-ott-7-1423] In this study, we found that the *KRAS*/*HER2*/*BRAF* mutations identified a distinct subgroup of patients with stage IIIA tumors who showed early recurrence even after they received adjuvant chemotherapy; therefore, more aggressive perioperative treatment of these patients might be warranted. We also revealed that the histological pattern group was not an independent predictor of survival for the subcohort of patients harboring a wild-type *EGFR* gene, suggesting that the genetic classification might also supersede morphological classification for prognosis prediction.

Although strengthened by the consecutively collected, completely resected samples as well as the large sample size, several limitations of the current study still need to be noted. First, we only considered the predominant histological pattern in our analysis. However, this might not interfere with the result, as previous studies have sufficiently proved that only the predominant pattern plays a role in survival prediction,[@b17-ott-7-1423] and there might not be intratumoral heterogeneity for mutation analysis in mixed-subtype tumors.[@b23-ott-7-1423] Second, the use of *EGFR* TKIs, radiation therapy data was not included. Therefore, further investigation into whether the patients with an *EGFR* mutant gene have different responses to *EGFR* TKIs of radiation therapy considering their morphological subtype would be of great value.

Conclusion
==========

This study demonstrated that the novel IASLC/ATS/ERS classification was associated with oncogenic mutations, which further increases our understanding of interindividual variation among lung adenocarcinomas and helps to stratify the mutational analysis strategy in clinical practice. The combination of these two systems provides essential information for specialized treatment, and their combined impact for targeted therapy still requires further investigation. The histological subtype based algorithm is an efficient implement to the CAP/IASLC/AMP molecular testing guideline for East Asian patients.

Supplementary materials
=======================

###### 

Flow chart of the study design.

**Abbreviations:** LADC, lung adenocarcinoma; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma.

###### 

Overall mutation spectrum of 981 lung adenocarcinomas.

**Note:** \*Indicates samples harboring *PIK3CA* mutation without overlap with other driver mutations.

###### 

RFS and OS of IA and IMA.

**Notes:** RFS (**A**) and OS (**B**) of 478 IA and 17 IMA. Pattern group 1 includes LEP predominant pattern. Pattern group 2 includes acinar and PAP patterns. Pattern group 3 includes solid and MP patterns.

**Abbreviations:** RFS, relapse-free survival; OS, overall survival; IA, invasive adenocarcinomas; IMA, invasive mucinous adenocarcinomas; LEP, lepidic predominant; PAP, papillary predominant; MP, micropapillary predominant.

###### 

IA by driver mutations.

**Notes:** RFS (**A**) and OS (**B**) of 478 invasive adenocarcinomas by driver mutations.

**Abbreviations:** IA, invasive adenocarcinomas; RFS, relapse-free survival; OS, overall survival.

###### 

Univariate analysis for correlation between mutations and clinicopathological characteristics in 901 invasive adenocarcinomas

                             All   *EGFR*   *KRAS*   *HER2*        *BRAF*   *ALK*   *RET*         *PIK3CA[\*](#tfn4-ott-7-1423){ref-type="table-fn"}*   Pan-negative                                                                                                                         
  -------------------------- ----- -------- -------- ------------- -------- ------- ------------- ----------------------------------------------------- -------------- ------------- ---- ----- ----------- ---- ------ ------------- ---- ----- ----------- ---- ----- ------- ----- ------ -------------
  Age                                                0.470                          0.250                                                                              0.156                    0.774                   0.072                    0.084                  0.759                0.071
   \<60                      441   293      66.4                   30       6.8                   12                                                    2.7                          5    1.1               29   6.6                  9    2.0               14   3.2           61    13.8   
   ≥60                       460   316      68.7                   23       5.0                   6                                                     1.3                          7    1.5               18   3.9                  3    0.7               13   2.8           84    18.3   
  Sex                                                \<**0.001**                    \<**0.001**                                                                        \<**0.001**              **0.042**               0.126                    0.563                  0.256                \<**0.001**
   Male                      404   216      53.5                   47       11.6                  1                                                     0.2                          9    2.2               16   4.0                  4    1.0               15   3.7           108   26.7   
   Female                    497   393      79.1                   6        1.2                   17                                                    3.4                          3    0.6               31   6.2                  8    1.6               12   2.4           37    7.4    
  Smoke                                              \<**0.001**                    \<**0.001**                                                                        **0.001**                **0.003**               0.083                    0.355                  0.086                \<**0.001**
   Never                     605   475      78.5                   13       2.1                   18                                                    3.0                          3    0.5               37   6.1                  10   1.7               14   2.3           47    7.8    
   Ever                      296   134      45.3                   40       13.5                  0                                                     0.0                          9    3.0               10   3.4                  2    0.7               13   4.4           98    33.1   
  Pathologic stage                                   **0.023**                      0.494                                                                              0.210                    0.359                   0.575                    0.122                  0.780                0.130
   I--II                     590   414      70.2                   37       6.3                   9                                                     1.5                          6    1.0               29   4.9                  5    0.8               17   2.9           87    14.7   
   III--IV                   311   195      62.7                   16       5.1                   9                                                     2.9                          6    1.9               18   5.8                  7    2.3               10   3.2           58    18.6   
  Pathologic T stage                                 **0.024**                      0.444                                                                              0.813                    0.576                   0.693                    **0.021**              0.117                \<**0.001**
   pT1                       477   318      71.1                   29       6.5                   8                                                     1.8                          7    1.6               22   4.9                  10   2.2               9    2.0           51    11.4   
   pT2--4                    454   291      64.1                   24       5.3                   10                                                    2.2                          5    1.1               25   5.5                  2    0.4               18   4.0           94    20.7   
  Predominant pattern                                \<**0.001**                    \<**0.001**                                                                        0.347                    0.463                   0.560                    **0.011**              0.308                \<**0.001**
   Nonsolid                  738   549      74.4                   34       4.6                   13                                                    1.8                          9    1.2               37   5.0                  6    0.8               20   2.7           87    11.8   
   Solid                     163   60       36.8                   19       11.7                  5                                                     3.1                          3    1.8               10   6.1                  6    3.7               7    4.3           58    35.6   
  Minor mucinous component                           \<**0.001**                    0.782                                                                              **0.032**                0.202                   \<**0.001**              **0.046**              0.713                0.759
   Without                   838   585      69.8                   49       5.8                   14                                                    1.7                          10   1.2               32   3.8                  9    1.1               25   3.0           134   16.0   
   With                      63    24       38.1                   4        6.3                   4                                                     6.3                          2    3.2               15   23.8                 3    4.8               2    3.2           11    17.5   

**Notes:**

*PIK3CA* overlapped with 17 *EGFR*, four *KRAS*, and one *RET. P*-values less than 0.05 are shown in bold.

###### 

Multivariate analysis for correlation with *EGFR* mutation and pan-negative samples in 901 invasive adenocarcinomas

                                                   *EGFR*        Pan-negative                                     
  ------------------------------------------------ ------------- -------------- ------------ ------------- ------ ------------
  Age (≥60 versus \<60)                            0.939         1.01           0.74--1.39   **0.030**     1.56   1.04--2.33
  Sex (female versus male)                         0.266         1.31           0.81--2.11   0.396         0.75   0.39--1.45
  Smoke (ever versus never)                        \<**0.001**   0.30           0.18--0.48   \<**0.001**   4.00   2.14--7.48
  Pathologic stage (III--IV versus I--II)          0.876         0.97           0.69--1.37   0.691         0.92   0.61--1.39
  Pathologic T stage (pT2--4 versus pT1)           0.765         1.05           0.76--1.46   0.055         1.50   0.99--2.28
  Predominant pattern (solid versus nonsolid)      \<**0.001**   0.24           0.16--0.36   \<**0.001**   3.20   2.07--4.93
  Minor mucinous component (with versus without)   \<**0.001**   0.22           0.12--0.39   0.883         1.06   0.50--2.23

**Note:** *P*-values less than 0.05 are shown in bold.

**Abbreviations:** OR, odds ratio; CI, confidence interval.

###### 

List of three variants of IAs and four stage III--IV LEP adenocarcinomas

  Patient \#   Sex      Age (year)   Smoking (pack-year)   Diameter (cm)   pT   pN   pM   Stage   Mutation       Predominant pattern
  ------------ -------- ------------ --------------------- --------------- ---- ---- ---- ------- -------------- ---------------------
  1            Female   46           0                     4.0             2a   0    0    IB      Pan-negative   Enteric
  2            Male     55           30                    3.0             2a   1    0    IIB     Pan-negative   Enteric
  3            Male     68           35                    3.5             2a   0    0    IB      *KRAS*         Colloid
  4            Male     37           0                     4.0             2a   2    0    IIIA    *EGFR*         Lepidic
  5            Female   52           0                     2.5             4    0    0    IIIA    *EGFR*         Lepidic
  6            Male     34           17                    1.2             2a   2    0    IIIA    *EGFR*         Lepidic
  7            Female   48           0                     1.0             4    0    1    IV      *EGFR*         Lepidic

**Abbreviations:** IAs, invasive adenocarcinomas; LEP, lepidic predominant; pT, pathologic tumor stage; pN, pathologic node stage; pM, pathologic metastasis stage.

###### 

Survival analysis for RFS and OS in 487 invasive adenocarcinomas

                                 RFS   OS                                                                     
  ------------------------------ ----- ----- ------ ------------ ------------- ----- ---- ------ ------------ -------------
  Age                                                            0.602                                        0.500
   \<60                          249   93    31.5   27.3--35.7                 249   35   45.2   39.1--51.4   
   ≥60                           229   73    30.8   25.9--35.7                 229   34   46.9   43.5--50.3   
  Sex                                                            **0.047**                                    0.063
   Male                          211   90    29.6   25.2--34.0                 211   40   43.8   37.6--5.0    
   Female                        267   76    32.1   27.1--37.2                 267   29   48.0   44.4--51.5   
  Smoking                                                        **0.007**                                    0.092
   Never                         317   94    31.8   27.1--36.4                 317   38   46.6   42.5--5.6    
   Ever                          161   72    28.2   23.2--33.2                 161   31   46.8   43.2--5.4    
  IASLC stage                                                    \<**0.001**                                  \<**0.001**
   IA                            153   27    40.1   33.6--46.5                 153   6    55.1   52.7--57.6   
   IB                            96    19    30.8   26.3--35.2                 96    7    50.8   46.4--55.3   
   IIA                           53    21    33.3   25.6--41.0                 53    10   46.1   39.3--52.9   
   IIB                           14    6     20.9   13.4--28.4                 14    2    35.4   3.3--4.6     
   IIIA                          162   93    17.7   15.2--2.2                  162   44   33.6   3.8--36.5    
  Adjuvant CTX, total                                            \<**0.001**                                  \<**0.001**
   No                            247   53    35.8   3.5--41.2                  247   14   53.6   51.3--56.0   
   Yes                           231   113   26.1   22.4--29.9                 231   55   41.4   37.3--45.6   
  Adjuvant CTX, stage II--IIIA                                   0.256                                        0.827
   No                            36    19    14.4   11.1--17.6                 36    9    31.7   26.7--36.6   
   Yes                           193   101   23.9   19.9--28.0                 193   47   40.6   36.1--45.2   
  Pattern group                                                  \<**0.001**                                  **0.018**
   1                             40    4     50.8   43.7--58.0                 40    1    56.3   52.6--59.9   
   2                             330   102   30.9   26.5--35.2                 330   44   47.3   43.5--51.1   
   3                             108   60    19.4   16.2--22.6                 108   24   35.3   32.0--38.6   
  Minor mucinous component                                       0.472                                        0.885
   Without                       443   155   30.4   26.6--34.1                 443   64   47.0   43.9--5.1    
   With                          35    11    26.7   21.3--32.1                 35    5    35.2   31.2--39.3   
  Mutations                                                      0.353                                        225
   Pan-negative                  73    27    26.0   21.2--3.9                  73    14   37.3   33.1--41.6   
   Mutant                        405   139   30.7   26.9--34.5                 405   55   46.9   43.3--5.5    
  *EGFR*                                                         0.185                                        **0.019**
   Wild-type                     165   65    32.8   28.2--37.4                 165   34   45.7   41.9--49.5   
   Mutant                        313   101   29.9   25.8--34.0                 313   35   47.3   43.3--51.3   
  *KRAS*                                                         0.529                                        0.126
   Wild-type                     445   151   29.5   25.7--33.4                 445   60   46.7   43.4--49.9   
   Mutant                        33    15    33.5   24.4--42.6                 33    9    44.8   37.2--52.5   
  *HER2*                                                         0.129                                        0.081
   Wild-type                     466   160   30.7   27.0--34.4                 466   65   47.1   44.0--5.2    
   Mutant                        12    6     16.5   9.1--23.9                  12    4    27.3   2.8--33.9    
  *BRAF*                                                         0.077                                        0.321
   Wild-type                     470   161   30.8   27.1--34.5                 470   67   46.9   43.8--5.0    
   Mutant                        8     5     15.4   6.3--24.5                  8     2    24.7   17.3--32.1   
  *ALK*                                                          0.478                                        0.699
   Wild-type                     451   159   30.4   26.7--34.1                 451   66   46.7   43.5--49.8   
   Mutant                        27    7     23.5   19.2--27.8                 27    3    36.2   31.6--4.8    
  *RET*                                                          0.756                                        0.974
   Wild-type                     467   161   30.4   26.7--34.1                 467   67   46.8   43.7--49.9   
   Mutant                        11    5     27.1   19.5--34.6                 11    2    33.8   26.9--4.6    
  *PIK3CA*                                                       0.438                                        0.604
   Wild-type                     461   161   30.3   26.6--34.0                 461   67   46.7   43.6--49.8   
   Mutant                        17    5     24.2   18.4--29.9                 17    2    39.8   34.1--45.5   

**Note:** *P*-values less than 0.05 are shown in bold.

**Abbreviations:** RFS, relapse-free survival; OS, overall survival; IASLC, International Association for the Study of Lung Cancer; CTX, chemotherapy; CI, confidence interval.

###### 

Categories of EGFR mutations

                                                        n     \%
  ----------------------------------------------------- ----- -------
  Sensitizing mutations alone                                 
   G719X                                                9     0.9%
   G719X, deletion                                      1     0.1%
   G719X, L861Q                                         2     0.2%
   Deletion                                             272   27.7%
   L858R                                                278   28.3%
   L861Q                                                7     0.7%
  Resistance mutations                                        
   S768I                                                2     0.2%
   S768I, exon 20 other (insertion)                     4     0.4%
   Exon 20 other (insertion)                            31    3.2%
  Combination of sensitizing and resistance mutations         
   G719X, T790M                                         1     0.1%
   G719X, S768I                                         5     0.5%
   Deletion, T790M                                      4     0.4%
   Deletion, exon 20 other (insertion)                  1     0.1%
   T790M, L858R                                         5     0.5%
   S768I, L858R                                         4     0.4%
   L858R, exon 20 other (insertion)                     3     0.3%
   L861Q, exon 20 other (insertion)                     1     0.1%
  Others                                                      
   E709_T710\>D                                         4     0.4%
   Exon 19 insertion                                    1     0.1%
  Negative                                              346   35.3%
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![Driver mutation spectrum, according to the novel IASLC/ATS/ERS classification.\
**Note:** \*Indicates samples harboring the *PIK3CA* mutation without overlap with other driver mutations.\
**Abbreviations:** IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LEP, lepidic predominant; ACN, acinar predominant; PAP, papillary predominant; MP, micropapillary predominant; SLD, solid predominant; IMA, invasive mucinous adenocarcinoma.](ott-7-1423Fig1){#f1-ott-7-1423}

![Driver mutation spectrum of 901 invasive adenocarcinomas, according to presence of minor mucinous component, smoking status, and solid predominant pattern.\
**Note:** \*Indicates samples harboring the *PIK3CA* mutation without overlap with other driver mutations.](ott-7-1423Fig2){#f2-ott-7-1423}

![RFS and OS of stage IIIA patients who received adjuvant chemotherapy.\
**Notes:** RFS (**A**) and OS (**B**) of stage IIIA patients who received adjuvant chemotherapy. MT, indicative of patients harboring either of *HER2*, *KRAS,* or *BRAF* mutations. WT, indicative of patients harboring wild-type *HER2*, *KRAS,* and *BRAF* genes. Pattern group 2 includes acinar and papillary predominant patterns. Pattern group 3 includes solid and micropapillary predominant patterns.\
**Abbreviations:** RFS, relapse-free survival; OS, overall survival; MT, mutant; WT, wild type.](ott-7-1423Fig3){#f3-ott-7-1423}

![Proposed mutation analysis strategy based on IASLC/ATS/ERS classification.\
**Abbreviations:** IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma.](ott-7-1423Fig4){#f4-ott-7-1423}

###### 

Characteristics of patients by IASLC/ATS/ERS classification

  ---------------------------------------------------------------------------------------------------------------
                       AAH/AIS (%)\   MIA (%)\   Invasive adenocarcinoma   IMA (%)\                        
                       N=13           N=20                                 N=44                            
  -------------------- -------------- ---------- ------------------------- ---------- ------ ------ ------ ------
  Age (years)                                                                                              

   \<60                61.5           55.0       46.5                      47.3       48.4   25.0   58.9   63.6

   ≥60                 38.5           45.0       53.5                      52.7       51.6   75.0   41.1   36.4

  Sex                                                                                                      

   Male                15.4           25.0       25.4                      41.0       49.0   41.7   61.3   36.4

   Female              84.6           75.0       74.6                      59.0       51.0   58.3   38.7   63.6

  Smoking                                                                                                  

   Never               92.3           100.0      83.1                      71.3       66.5   70.8   47.9   70.5

   Ever                7.7            0.0        16.9                      28.7       33.5   29.2   52.1   29.5

  Pathologic stage                                                                                         

   IA                  100.0          100.0      74.6                      37.7       28.4   20.8   12.9   34.1

   IB                                            19.7                      18.4       19.4   12.5   12.9   15.9

   IIA                                           0.0                       10.0       11.0   16.7   17.8   15.9

   IIB                                           0.0                       1.6        6.5    8.3    3.1    6.8

   IIIA                                          4.2                       25.2       28.4   41.7   44.8   25.0

   IIIB                                          0.0                       2.0        0.6    0.0    4.3    0.0

   IV                                            1.4                       4.9        5.8    0.0    4.3    2.3

  Pathologic T stage                                                                                       

   pT1                 100.0          100.0      76.1                      54.1       44.5   45.8   30.1   36.4

   pT2--T4                                       23.9                      45.9       55.5   54.2   69.9   63.6
  ---------------------------------------------------------------------------------------------------------------

**Abbreviations:** IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LEP, lepidic predominant; ACN, acinar predominant; PAP, papillary predominant; MP, micropapillary predominant; SLD, solid predominant; IMA, invasive mucinous adenocarcinoma.

###### 

Multivariate survival analysis for RFS and OS

                                       RFS (All, N=478)   RFS (*EGFR* WT, N=165)   OS (All, N=478)   OS (*EGFR* WT, N=165)                                                                                  
  ------------------------------------ ------------------ ------------------------ ----------------- ----------------------- ------------ ------------- ------ ------------ ----------- ------ ------------ -----------
  Age (≥60 versus \<60)                1.02               0.75--1.40               0.891             0.99                    0.59--1.65   0.956         1.47   0.91--2.38   0.119       1.86   0.91--3.77   0.087
  Sex (female versu's male)            1.00               0.62--1.62               0.993             0.78                    0.36--1.69   0.528         0.74   0.38--1.46   0.389       0.68   0.26--1.74   0.416
  Smoking (ever versus never)          1.42               0.87--2.32               0.166             1.01                    0.49--2.05   0.988         0.87   0.44--1.72   0.687       0.57   0.24--1.37   0.209
  Pathologic stage                     1.47               1.29--1.67               \<**0.001**       1.58                    1.30--1.91   \<**0.001**   1.39   1.13--1.70   **0.002**   1.43   1.08--1.91   **0.013**
  Pattern group                        1.72               1.26--2.33               **0.001**         1.56                    0.95--2.54   0.077         1.22   0.76--1.96   0.406       1.30   0.67--2.54   0.435
  Adjuvant CTX (with versus without)   0.85               0.54--1.33               0.477             0.53                    0.28--0.99   **0.048**     1.79   0.87--3.68   0.111       1.21   0.5--2.95    0.668
  *EGFR* mutation (MT versus WT)       1.25               0.88--1.79               0.209             --                      --           --            0.67   0.40--1.13   0.133       --     --           --

**Note:** *P*-values less than 0.05 are shown in bold.

**Abbreviations:** RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CTX, chemotherapy; MT, mutant; WT, wild type.
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